A Common Pathogenic Mechanism Linking Type-2 Diabetes and Alzheimer's Disease: Evidence from Animal Models
Open Access
- 1 January 2011
- journal article
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 7 (1), 10-18
- https://doi.org/10.3988/jcn.2011.7.1.10
Abstract
The failure of large-scale drug trials targeting the amyloidogenic pathway in Alzheimer's disease (AD) is increasing the need to identify a novel pathogenic mechanism. Studies finding a relationship between sporadic AD and type-2 diabetes mellitus (T2DM) are now receiving more attention. The risk for developing both T2DM and sporadic AD increases exponentially with age, and having T2DM doubles the risk of developing AD. The postmortem brains of AD patients show altered activities of insulin receptors and downstream molecules, as well as reduced protein and mRNA levels of insulin. More-recent laboratory research using animal models has identified mechanisms that are shared by diabetes and AD. Exogenous application of streptozotocin, which disrupts systemic insulin secretion, results in insulin deficiency, increased tau phosphorylation, and cognitive impairments that can be reversed by exogenous insulin supplementation. However, AD pathology is more severe in T2DM animal models exhibiting hyperinsulinemia and insulin resistance, and this is not modulated by insulin. The symptoms of this AD pathology included increased tau phosphorylation at multiple sites, increased tau cleavage, and greater neuronal and synaptic damage, even with increased amyloid β protein production. It has therefore been suggested that hyperinsulinemia and insulin resistance represent major factors underlying AD in T2DM. A recent study involving cross-mating ob/ob and amyloid precursor protein transgenic mice provided evidence that T2DM and AD aggravate each other, and suggested that cerebral vessels constitute an important substrate that is commonly damaged by the two major disorders. Given the evidence provided by animal models, further investigation of the mechanisms underlying T2DM in AD should help to identify potential treatment targets in AD.Keywords
This publication has 62 references indexed in Scilit:
- Caspase activation precedes and leads to tanglesNature, 2010
- Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetesProceedings of the National Academy of Sciences, 2010
- Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic miceBiochemical and Biophysical Research Communications, 2009
- Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's diseaseBrain, 2009
- The Insulin/Akt Signaling Pathway Is Targeted by Intracellular β-AmyloidMolecular Biology of the Cell, 2009
- Recent developments in Alzheimer's disease therapeuticsBMC Medicine, 2009
- Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomersProceedings of the National Academy of Sciences of the United States of America, 2009
- Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neuronsNature Neuroscience, 2008
- The GSK3 hypothesis of Alzheimer’s diseaseJournal of Neurochemistry, 2007
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996